Tesamorelin Clinical Evidence Guide: 2026 Medical Standards
Last updated: June 7, 2026 Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). Unlike the majority of performance peptides, Tesamorelin possesses a robust, FDA-cleared safety and efficacy profile. Under 2026 clinical standards, it is utilized as the premier pharmacological agent for selectively oxidizing visceral adipose tissue (VAT) and upregulating endogenous growth hormone without … Read more